Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor

Pharmacology Research and Perspectives

Volumn 1, Issue 2, 2013, Pages

  Slack, Robert J ^a   Russell, Linda J ^a   Barton, Nick P ^a   Weston, Cathryn ^a,b   Nalesso, Giovanna ^a,c   Thompson, Sally Anne ^a   Allen, Morven ^a   Chen, Yu Hua ^a   Barnes, Ashley ^a   Hodgson, Simon T ^a,d   Hall, David A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Stevenage Bioscience Catalyst   (United Kingdom)

Author keywords

Allosteric modulator; CCL17; CCL22; CCR4; CCR4 antagonist; chemokine; T cell

Indexed keywords

EID: 84894465088     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.19     Document Type: Article

References (37)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to receptors and channels (GRAC), 5th edition (2011). Br J Pharmacol 164: S1–S324.
2. Andrews G, Jones C, Wreggett KA (2008). An intracellular allosteric site for a specific class of antagonist of the CC-chemokine G-protein-coupled receptors CCR4 and CCR5. Mol Pharmacol 73: 855–867.
3. Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, et al. (2003). CCR2: characterisation of the antagonist binding site from a combined receptor modelling/mutagenesis approach. J Med Chem 46: 4070–4086.
4. Bonecchi R, Bianchi G, Panina-Bourdignon P, D'Ambrosio D, Lang R, Borsatti A, et al. (1998). Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187: 129–134.
5. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al. (1999). The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400: 776–780.
6. Cheng Y-C, Prusoff WH (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108.
7. Christopoulos A, Mitchelson F (1994). Assessment of the allosteric interactions of the bisquaternary heptane-1, 7-bis(dimethyl-3′-phthalimidopropyl)ammonium bromide at M1 and M3 muscarine receptors. Mol Pharmacol 46: 106–114.
8. Clemetson KJ, Clemetson JM, Proudfoot AEI, Power CA, Baggiolini M, Wells TNC (2000). Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 96: 4046–4054.
9. De Léan A, Stadel JM, Lefkowitz RJ (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 255: 7108–7117.
10. Ehlert FJ (1988). Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33: 187–194.
11. Hall DA (2000). Modelling the functional effects of allosteric modulators of pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58: 1412–1423.
12. Hall DA (2006). Predicting dose-response curve behaviour: mathematical models of allosteric receptor-ligand interactions. Pp. 39–78 in N. G. Bowery, ed. Allosteric receptor modulation in drug targeting. Taylor & Francis, New York, NY.
13. Hall DA (2013) Application of receptor theory to allosteric modulation of receptors. Pp. 217–290 in T. Kenakin, ed. Progress in molecular biology and translational science, vol. 115. Academic Press, Elsevier Inc, Oxford, UK.
14. + regulatory T cells. J Exp Med 194: 847–853.
15. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A (2005). Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and CCL11 as markers of severity of atopic dermatitis. Allergy 60: 685–688.
16. Juremalm M, Olsson N, Nilsson G (2002). Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. Biochem Biophys Res Commun 297: 480–485.
17. Larche M, Robinson D, Kay AB (2003). The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 111: 450–463.
18. Leff P, Dougall IG (1993). Further concerns over Cheng-Prusoff analysis. Trends Pharmacol Sci 14: 110–112.
19. Lezcano-Meza D, Negrete-Garcia MC, Dante-Escobedo M, Teran LM (2003). The monocyte-derived chemokine is released in the bronchoalveolar lavage fluid of steady-state asthmatics. Allergy 58: 1125–1130.
20. + regulatory T cells. J Immunol 180: 122–129.
21. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al. (2000). International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145–176.
22. Nalesso G, Weston C, Slack R, Hall D (2008) The chemokine CCL11 (eotaxin) is an antagonist of CCR4. From the Winter Meeting, 2008: Proceedings of the British Pharmacological Society at http://www.pa2online.org/abstracts/Vol6Issue4abst070P.pdf
23. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, et al. (2008). Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors CXCR1 and CXCR2. Mol Pharmacol 74: 1193–1202.
24. Nouri-Aria KT, Wilson D, Francis JN, Jopling LA, Jacobson MR, Hodge MR, et al. (2002). CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol 32: 1933–1938.
25. Panina-Boudignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellattato C, et al. (2001). The CC-chemokine receptors CCR4 and CCR8 identify airway T cells of allergen challenged atopic asthmatics. J Clin Invest 107: 1357–1364.
26. Paton WDM, Rang H (1965). The uptake of atropine and related drugs by intestinal smooth muscle of the guinea pig in relation to acetylcholine receptors. Proc R Soc Lond B Biol Sci 163: 1–44.
27. Purandare AV, Somerville JE (2006). Antagonists of CCR4 as immunomodulatory agents. Curr Top Med Chem 6: 1335–1344.
28. Rosenkilde MM, Schwartz TW (2006). GluVII:06 – a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr Top Med Chem 6: 1319–1333.
29. Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, et al. (2010). A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol 159: 1429–1439.
30. Sebastiani S, Danelon G, Gerber B, Uguccioni M (2005). CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of the first β-strand of chemokine. Eur J Immunol 35: 746–756.
31. Slack RJ, Hall DA (2012). Development of operational models of receptor activation including constitutive receptor activity and their use to determine the efficacy of the chemokine CCL17 at the CC-chemokine receptor CCR4. Br J Pharmacol 166: 1776–1792.
32. Slack RJ, Russell LJ, Hall DA, Luttmann MA, Ford AJ, Saunders KA, et al. (2011). Pharmacological characterisation of GSK1004723, a novel, long-acting antagonist at H1 and H3 receptors. Br J Pharmacol 164: 1627–1641.
33. Wang Y, Zhang Y, Yang X, Han W, Liu Y, Xu Q, et al. (2006). Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). Life Sci 78: 614–621.
34. Weber G (1975). Energetics of ligand binding to proteins. Adv Protein Chem 29: 1–83.
35. Wise EL, Duchesnes C, da Fonseca PCA, Allen RA, Williams TJ, Pease JE (2007). Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J Biol Chem 282: 27935–27943.
36. Xia M, Sui Z (2009). Recent developments in CCR2 antagonists. Expert Opin Ther Pat 19: 295–303.
37. Zlotnik A, Yoshie O (2000). Chemokines: a new classification system and their role in immunity. Immunity 12: 121–127.